Edwards Lifesciences (EW) Q2 2026 earnings review
Guidance Raised as TMTT Surges, Though Tax Hit Skews GAAP Bottom Line
Edwards Lifesciences delivered a highly robust Q2, beating expectations with 12.5% constant currency revenue growth. The structural heart portfolio is firing on all cylinders: TAVR grew a durable 10.5%, while the TMTT segment skyrocketed 44.8%. This broad-based strength led management to raise full-year sales and TAVR guidance. However, beneath the surface of a $0.78 adjusted EPS beat, GAAP net income collapsed 28% year-over-year due to a massive $188 million valuation allowance triggered by new California tax laws. Operationally, the company is thriving; statutorily, it took a hit.
🐂 Bull Case
The Transcatheter Mitral and Tricuspid Therapies segment grew nearly 45% (CC) to $196 million, proving Edwards has successfully cultivated a massive second pillar alongside TAVR.
Management increased FY26 total sales constant currency growth guidance to 10-11% (from 9-11%) and bumped up expectations for both the TAVR and TMTT segments.
🐻 Bear Case
A new California law limiting R&D credit carryovers resulted in a $188.2M hit. This pushes the go-forward effective tax rate to the high end of the 16-19% range.
Despite top-line outperformance, gross margins are pinned at the lower end of the 78-79% FY guidance due to persistent foreign exchange hedging pressures.
⚖️ Verdict: 🟢
Bullish. The core business is accelerating, with TMTT scaling rapidly and TAVR maintaining double-digit growth. The GAAP tax hit is a one-time paper pain, but the underlying cash generation and clinical momentum are superb.
Key Themes
TMTT: From Concept to Blockbuster
TMTT is officially scaling. Second-quarter sales hit $195.9 million, up 44.8% on a constant currency basis. Growth is broad-based across the PASCAL repair system and EVOQUE replacement valves. With the next-generation PASCAL with Capture Clarity expected to secure U.S. and European approvals in Q4, this segment is reliably marching toward management's long-term $2 billion target.
Clinical Evidence Deepens the TAVR Moat
TAVR grew 10.5% (CC) to $1.26 billion. The growth is heavily supported by undeniable clinical data presented at New York Valves: 7-year PARTNER 3 data validating SAPIEN's long-term durability and 5-year EARLY TAVR data supporting intervention earlier in the disease pathway. This data is actively shifting clinical dogma away from 'watchful waiting'.
Operating Leverage Kicks In
Adjusted operating profit margin expanded to 30.0% (up from 28.2% a year ago). A key driver is the strategic scaling of R&D expenses, which fell to 16.0% of sales from 18.0% in 25Q2. Top-line growth is now comfortably outpacing R&D growth, delivering the operating leverage management promised at prior investor days.
GAAP Income Collapses Under California Tax Law
Despite the aggressively positive narrative around the $0.78 adjusted EPS beat, GAAP net income actually plunged 28% year-over-year to $241.4 million. The culprit: a $188.2 million valuation allowance against deferred tax assets, triggered by new California legislation permanently restricting the use of R&D tax credits. This forces the company's effective tax rate to the high end of its 16-19% guidance range.
Gross Margin Capped by FX
Adjusted gross margin was 77.6%, essentially flat year-over-year. While manufacturing efficiency improved, it was entirely offset by foreign exchange headwinds. Consequently, management lowered expectations, stating FY26 gross margins will come in at the 'lower end' of their 78-79% guidance range.
Loss on Impairment Continues
Edwards recorded a $40 million impairment loss in Q2 because it decided not to exercise an option to acquire a variable interest entity (VIE). This follows a separate $123.6 million VIE impairment in Q1. While backed out of adjusted earnings, these write-offs indicate some external bets are failing to materialize.
Macro Catalyst: CMS NCD Reconsideration
A major macro regulatory event approaches in September: the Centers for Medicare & Medicaid Services (CMS) is expected to issue a final decision memo regarding the National Coverage Determination (NCD) for TAVR. A favorable ruling could significantly advance therapy access for Medicare beneficiaries, acting as a tailwind for 2027 and beyond.
Other KPIs
Stable. Up 5.0% on a constant currency basis. Growth is anchored by the adoption of RESILIA tissue therapies (INSPIRIS, MITRIS, KONECT). The segment received a boost from 10-year COMMENCE trial data showing highly favorable freedom from structural valve deterioration.
The balance sheet remains pristine. With total debt of just $600 million, the company holds massive net cash, leaving ample firepower for the $1.5 billion remaining under its share repurchase authorization or future bolt-on M&A.
Guidance
Accelerating. Raised from previous guidance of 9% to 11%. This reflects outperformance in the first half of the year across all major business units.
Accelerating. Raised from 7% to 9%. Absolute revenue is projected at $4.75B to $5.0B. Management is confident that long-term durability data will continue to shift physician behavior.
Accelerating. Raised the floor from the prior $740-$780 million range. The segment is capitalizing on the simultaneous scaling of PASCAL and EVOQUE.
Stable. Reaffirmed despite the updated assumption that the effective tax rate will hit the high end of the 16-19% range, signaling immense underlying operational strength.
Stable. The midpoint of $1.67 billion represents a slight sequential deceleration from Q2's $1.74 billion, typical of summer seasonality in elective/semi-elective structural heart procedures.
Key Questions
Impact of California Tax Law on R&D Strategy
With the new California legislation permanently restricting R&D credits and resulting in a $188 million valuation allowance, is Edwards considering shifting R&D headcount or investments to more tax-favorable jurisdictions?
TAVR Organic Growth vs. Competitor Exit
You raised the TAVR constant currency growth guidance to 8-9%. How much of this continued momentum is organic market expansion via the 'Early TAVR' data versus a sustained capture of European market share following a competitor's exit earlier this year?
PROGRESS Trial Expectations
With the PROGRESS trial baseline characteristics now presented at New York Valves, what specific heterogeneous traits in the moderate AS population are making you the most optimistic heading into the full data readout at TCT?
Variable Interest Entity Impairments
We've seen over $160 million in impairment losses across Q1 and Q2 related to Variable Interest Entities. Has the company's framework for external early-stage investments changed given these write-downs?